1. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus. (August 2018) Authors: Doria, A; Bass, D; Schwarting, A; Hammer, A; Gordon, D; Scheinberg, M; Fox, N L; Groark, J; Stohl, W; Kleoudis, C; Roth, D Journal: Lupus Issue: Volume 27:Number 9(2018) Page Start: 1489 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus. (December 2017) Authors: Chatham, W; Chadha, A; Fettiplace, J; Kleoudis, C; Bass, D; Roth, D; Gordon, D Journal: Lupus Issue: Volume 26:Number 14(2017) Page Start: 1483 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SAT0231 Safety of subcutaneous belimumab in patients with systemic lupus erythematosus: a 6-month open-label extension study. (15th June 2017) Authors: Doria, A; Stohl, W; Schwarting, A; Scheinberg, M; Hammer, A; Kleoudis, C; Groark, J; Fox, NL; Roth, D; Bass, D; Gordon, D Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 861 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗